Pembrolizumab showed clinical benefit in malignant pleural mesothelioma

New approaches in computational pathology for risk assessment in benign breast diseases

Chk1 inhibition combined with standard dose gemcitabine may be safe and effective

Updated results on phase III CLL trial shows 90% response rate using ibrutinib

Latest trials and outcomes with new CLL treatments

Developing treatments for indolent non hodgkin lymphoma

The evolution of CLL treatment

Investigational PD-L1–targeted immunotherapy safe for patients with triple-negative breast cancer, effective in some

US breast cancer cases expected to increase by as much as 50 percent by 2030

Phase II trial of ipilimumab-nivolumab combo shows promise in advanced melanoma

New T cell–based immunotherapy shows promise for lethal stem cell transplant complication

Pembrolizumab promising for lung cancer, clinical outcomes correlate with biomarker